Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07861100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07861100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 26, 2026
Completion date
September 16, 2030
Enrollment
8,500 (estimated)
Sites
769

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular risk, obesity